LYEL - Lyell Immunopharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-46.37M

Cash

526.3M

Avg Qtr Burn

-39.87M

Short % of Float

9.82%

Insider Ownership

15.40%

Institutional Own.

67.18%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LYL797 Details Cancer, Solid tumor/s, Breast cancer, Non-small cell lung carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYL845 Details Solid tumor/s, Cancer, Melanoma, Colorectal cancer , Non-small cell lung carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYL119 Details Solid tumor/s, Cancer	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.